Receptor activator of nuclear factor-kappa B ligand (RANKL) is a member
of tumor necrosis factor (TNF) superfamily. It binds to Receptor
activator of NF-kB (RANK) and plays a major role in the regulation of
osteoclast function. Binding of RANKL to RANK leads to the activation of
signaling modules such as NF-kappa B, mitogen activated protein kinases
(MAPK's), protein kinase C (PKC), Ca2+/Calcineurin/nuclear factor of
activated T cells (NFAT) and phosphatidyl 3-kinase (PI3K). The
RANKL-RANK signaling system is negatively regulated by a decoy receptor
known as Osteoprotegerin.

There are today 192 companies plus partners developing 276 RANKL pathway
targeting drugs in 1051 developmental projects in cancer. In addition,
there is 1 suspended drug and the accumulated number of ceased drugs
over the last years amount to another 139 drugs.

Rankl Signaling Pathway In Oncology Drug Pipeline Update lists all drugs
and gives you a progress analysis on each one of them. Identified drugs
are linked to 136 different targets. All included targets have been
cross-referenced for the presence of mutations associated with human
cancer. To date 134 out of the 136 studied drug targets so far have been
recorded with somatic mutations.

The software application lets you narrow in on these mutations and links
out to the mutational analysis for each of the drug targets for detailed
information. All drugs targets are further categorized on in the
software application by 34 classifications of molecular function and
with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at a Glance

Investigators

Includes more than 192 principal companies plus their collaborators.
There is direct access from inside the application to web pages of all
principal companies.

Drug name & Synonyms

Lists commercial, generic and code names for drugs.

Developmental stage

This Drug Pipeline Update contains 276 RANKL pathway targeting drugs
in development, which have a total of 1051 developmental projects in
cancer. In addition there are suspended and ceased drugs.

Indications

Included RANKL pathway targeting drugs are also in development for 160
other indications, where of 107 are different cancer indications.